NCT00538876View on ClinicalTrials.gov

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

decitabine

"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."

Trial Locations (1)

10021

Weill Medical College of Cornell University, New York

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT00538876 - Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | Biotech Hunter | Biotech Hunter